AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.
You may also be interested in...
MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.
Start-Up Quarterly Statistics, Q4 2013
Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.
AstraZeneca’s Soriot Outlines Epanova Approach, Reviews Tough First Year As CEO
AstraZeneca’s two-pronged approach to get its experimental fish oil-based heart drug Epanova approved by U.S. regulators is on track according to CEO Pascal Soriot. But an FDA Advisory Committee’s negative recommendation for Amarin’s similar drug, Vascepa, likely means the second step, seeking a label expansion for Epanova in a broader, less seriously ill population, will have to await full outcomes data.